Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis.
Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas FR, Zhu B, Hong L, Aminu M, Saad MB, Salehjahromi M, Muneer A, Sujit SJ, Behrens C, Gibbons DL, Heymach JV, Kalhor N, Wistuba II, Solis Soto LM, Zhang J, Qin W, Wu J. Diao S, et al. Among authors: heymach jv. Cancers (Basel). 2023 Oct 1;15(19):4824. doi: 10.3390/cancers15194824. Cancers (Basel). 2023. PMID: 37835518 Free PMC article.
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Xu L, et al. Among authors: heymach jv. Oncogene. 2010 May 6;29(18):2616-27. doi: 10.1038/onc.2010.16. Epub 2010 Feb 15. Oncogene. 2010. PMID: 20154724 Free PMC article.
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Byers LA, et al. Among authors: heymach jv. Mol Cancer Ther. 2010 Jun;9(6):1755-63. doi: 10.1158/1535-7163.MCT-09-1047. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530716 Free PMC article.
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. Roybal JD, et al. Among authors: heymach jv. Mol Cancer Res. 2011 Jan;9(1):25-35. doi: 10.1158/1541-7786.MCR-10-0497. Epub 2010 Nov 29. Mol Cancer Res. 2011. PMID: 21115742 Free PMC article.
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Yang F, et al. Among authors: heymach jv. Cancer Res. 2011 Aug 15;71(16):5512-21. doi: 10.1158/0008-5472.CAN-10-2614. Epub 2011 Jul 1. Cancer Res. 2011. PMID: 21724587 Free PMC article.
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Xie Y, et al. Among authors: heymach jv. Clin Cancer Res. 2011 Sep 1;17(17):5705-14. doi: 10.1158/1078-0432.CCR-11-0196. Epub 2011 Jul 8. Clin Cancer Res. 2011. PMID: 21742808 Free PMC article.
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Pataer A, et al. J Thorac Oncol. 2012 May;7(5):825-32. doi: 10.1097/JTO.0b013e318247504a. J Thorac Oncol. 2012. PMID: 22481232 Free PMC article.
The BATTLE trial: personalizing therapy for lung cancer.
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. Kim ES, et al. Among authors: heymach jv. Cancer Discov. 2011 Jun;1(1):44-53. doi: 10.1158/2159-8274.CD-10-0010. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586319 Free PMC article. Clinical Trial.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Byers LA, et al. Among authors: heymach jv. Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6. Cancer Discov. 2012. PMID: 22961666 Free PMC article.
475 results